Hematopoietic stem cell transplantation for severe combined immunodeficiency in the neonatal period leads to superior thymic output and improved survival.

@article{Myers2002HematopoieticSC,
  title={Hematopoietic stem cell transplantation for severe combined immunodeficiency in the neonatal period leads to superior thymic output and improved survival.},
  author={Laurie A Myers and Dhavalkumar D. Patel and Jennifer M. Puck and Rebecca H Buckley},
  journal={Blood},
  year={2002},
  volume={99 3},
  pages={
          872-8
        }
}
All genetic types of severe combined immunodeficiency (SCID) can be cured by stem cell transplantation from related donors. The survival rate approaches 80%, and most deaths result from opportunistic infections acquired before transplantation. It was hypothesized that the survival rate and kinetics of immune reconstitution would be improved for infants receiving transplants in the neonatal period (first 28 days of life), prior to the development of infections. A 19.2-year retrospective… 

Figures and Tables from this paper

Transplantation of hematopoietic stem cells in human severe combined immunodeficiency: longterm outcomes

  • R. Buckley
  • Medicine, Biology
    Immunologic research
  • 2011
The longterm outcome, according to molecular type, of 166 consecutive SCID infants given non-conditioned related donor bone marrow transplants at this institution over the past 28.3 years is summarized and published reports of longterm outcomes of transplants in SCID performed at other centers are reviewed.

Transplantation outcomes for severe combined immunodeficiency, 2000-2009.

Transplants from donors other than matched siblings were associated with excellent survival among infants with SCID identified before the onset of infection.

Severe Combined Immunodeficiency Patients: Immune Recovery After Stem Cell Transplantation

While T-cell reconstitution is observed during the first years after HSCT in most patients with SCID, correction of B-cell function is often more problematic, generally, T- cell immunity recovers within about a year after HS CT, whereas B-cells immunity recovers more slowly.

Hematopoietic stem cell transplantation for severe combined immunodeficiency diseases.

Hematopoietic cell transplantation for correction of primary immunodeficiencies

The genetic basis of the majority of lethal PIDs has been defined, allowing more accurate studies of the natural history of the disorders without HCT intervention, and providing a compelling rationale for early transplantation in disorders with median survivals of 15–20 years.

Single-center analysis of long-term outcome after hematopoietic cell transplantation in children with congenital severe T cell immunodeficiency

We review clinical outcome and immune reconstitution in a consecutive series of 74 infants with severe T cell immunodeficiency who received hematopoietic cell transplantation (HCT) from January 1991

B-cell function in severe combined immunodeficiency after stem cell or gene therapy: a review.

  • R. Buckley
  • Medicine, Biology
    The Journal of allergy and clinical immunology
  • 2010

Reconstitution of T-cell compartment after in utero stem cell transplantation: analysis of T-cell repertoire and thymic output.

Data indicate that in utero transplantation of fetuses with B+ SCID allows generation of newly diversified T lymphocytes and ensures long-term reconstitution of cell-mediated immunity.

Long term Outcome of Non-Ablative Booster Bone Marrow Transplantation in Patients with Severe Combined Immunodeficiency

In several patients, the use of two parents as sequential donors resulted in striking T-and B-cell immune reconstitution and nonablative booster BMT can be lifesaving for SCID.

Stem cell transplantation for primary immunodeficiency diseases: the North American experience

  • S. PaiM. Cowan
  • Medicine, Biology
    Current opinion in allergy and clinical immunology
  • 2014
Advances in transplant outcomes for Wiskott–Aldrich syndrome and chronic granulomatous disease support the strategy of early transplantation before the onset of severe complications; additional multicenter studies are needed to fully define optimal approaches.
...

References

SHOWING 1-10 OF 27 REFERENCES

Thymic function after hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency.

The vestigial thymus in infants with severe combined immunodeficiency is functional and can produce enough T cells after bone marrow transplantation to provide normal immune function.

In utero hematopoietic stem cell transplantation. A status report.

Limited consensus among investigators on many important issues, such as the mode or timing of in utero transplantation, the ideal source or dose of donor cells, estimation of maternal and fetal risks, appropriate candidate diseases for treatment, and important ethical considerations in counseling and therapy are found.

In utero transplantation of stem cells in humans: immunological aspects and clinical follow-up of patients.

This procedure, for the first time used in humans, has demonstrated its feasibility and its efficacy: during early fetal development, foreign cells engraft readily and may result in cure or significant correction of a large variety of inherited diseases.

Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease.

A gene therapy trial for SCID-X1 was initiated, based on the use of complementary DNA containing a defective gammac Moloney retrovirus-derived vector and ex vivo infection of CD34+ cells, which provided full correction of disease phenotype and clinical benefit.

HUMAN SEVERE COMBINED IMMUNODEFICIENCY (SCID): GENETIC, PHENOTYPIC AND FUNCTIONAL DIVERSITY IN 95 INFANTS. • 41

The presence of NK function in ADA deficient, autosomal recessive, and some SCID's of unknown type, and abnormally low NK numbers and function in a majority of X-linked and Jak3-deficient SCIDs implies that some molecular lesions affect T, B and NK cells, but that others affect only T cells (ADA deficiency), and others T and B cells (possible recombinase abnormalities).

In utero haematopoietic stem cell transplantation: current perspectives and future potential.

It is imperative that consensus is reached quickly on issues such as cell numbers/cell types so that the benefits of this approach to treatment can be realised.

Treatment of X-linked severe combined immunodeficiency by in utero transplantation of paternal bone marrow.

The successful treatment of a fetus with the X-linked variant of severe combined immunodeficiency by the in utero transplantation of paternal bone marrow that was enriched with hematopoietic cell progenitors is reported.

Defective IL7R expression in T-B+NK + severe combined immunodeficiency

It is demonstrated that defective IL7R expression causes T–B +NK+ SCID, indicating that the T- cell, but not the NK-cell, defect in XSCID results from inactivation of IL-7Rα signalling.